Development status: Experimental

Gram-negative activity

Propensity to select resistant bacteria

Mechanism of Action/Target pathogen: Active against <i>Pseudomonas aeruginosa, Escherichia coli, Salmonella paratyphi, Shigella flexneri, Mycobacterium phlei, Mycobacterium avium, </i>and<i> Mycobacterium tuberculosis</i>; protein synthesis inhibitor (binds to ribosome at a similar site to kanamycin and amikacin)

Reason dropped: Shows ototoxicity

Additional information: Natural product from <i>Streptomyces griseoverticillatus </i>var. <i>tuberacticus</i>; progenitor of tuberactinomycin N, which is a derivative with greater potency and reduced toxicity